Page last updated: 2024-11-06

albendazole sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Albendazole sulfoxide is the major metabolite of the anthelmintic drug albendazole. It is formed in the liver by cytochrome P450 enzymes. Albendazole sulfoxide is believed to be the active form of the drug, and it is more potent than albendazole itself. Albendazole sulfoxide inhibits the polymerization of tubulin, which is essential for the growth and development of parasitic worms. This disruption of microtubule formation disrupts the parasite's ability to absorb nutrients and reproduce. Albendazole sulfoxide is used to treat a variety of parasitic infections, including hydatid disease, neurocysticercosis, and alveolar echinococcosis. Research on albendazole sulfoxide is ongoing to improve its efficacy and safety, and to investigate its potential for treating other diseases.'

albendazole sulfoxide: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID83969
CHEMBL ID1665
CHEBI ID16959
SCHEMBL ID321413
MeSH IDM0088608

Synonyms (91)

Synonym
AC-016
AB01275491-01
ricobendazole
rycobendazole
albendazole oxide
methyl [5-(propylsulfinyl)-1h-benzimidazol-2-yl]carbamate
CHEBI:16959 ,
(+-)-albendazole sulfoxide
albendazole sulphoxide
54029-12-8
albendazole sulfoxide
methoxy-n-[5-(propylsulfinyl)benzimidazol-2-yl]carboxamide
methyl n-(5-propylsulfinyl-1h-benzimidazol-2-yl)carbamate
D07106
albendazole oxide (inn)
C02809
albendazole s-oxide
methyl 5-(propylsulfinyl)-2-benzimidazolecarbamate
carbamic acid, (5-propylsulfinyl)-1h-benzimidazol-2-yl)-, methyl ester
albendazole oxyde [inn-french]
methyl (5-propylsulfoxy)2-benzimidazolecarbamate
rs 8852
albendazolum oxidum [inn-latin]
oxido de albendazol [inn-spanish]
HMS2090E05
CHEMBL1665
rycoben
rs-8852
rs8852
methyl n-(6-propylsulfinyl-1h-benzimidazol-2-yl)carbamate
albendazole oxide [inn:ban]
unii-j39b52tv34
j39b52tv34 ,
oxido de albendazol
albendazolum oxidum
albendazole oxyde
n-(6-propylsulfinyl-1h-benzimidazol-2-yl)carbamic acid methyl ester
A829917
AKOS015961126
FT-0621944
NCGC00253760-02
AS-7013
S1836
AKOS015905725
SCHEMBL321413
MLS006011133
smr004702911
NCGC00253760-01
cas-54029-12-8
tox21_113873
dtxsid4057768 ,
dtxcid5031557
methyl (5-(propylsulfinyl)-1h-benzo(d)imidazol-2-yl)carbamate
albendazole oxide [inn]
albendazole impurity b [ep impurity]
albendazole sulfoxide [mi]
(+/-)-albendazole sulfoxide
methyl n-(5-(propylsulfinyl)-1h-benzimidazol-2-yl)carbamate
[5-(propylsulfinyl)-1h-benzimidazol-2-yl]carbamic acid, methyl ester
VXTGHWHFYNYFFV-UHFFFAOYSA-N
methyl n-[5-(propane-1-sulfinyl)-1h-1,3-benzodiazol-2-yl]carbamate
methyl 5-(propylsulfinyl)-1h-benzo[d]imidazol-2-ylcarbamate
AB01275491_02
carbamic acid, [5-(propylsulfinyl)-1h-benzimidazol-2-yl]-, methyl ester
mfcd00797922
J-519545
sr-05000001502
SR-05000001502-1
ricobendazole, >=98% (hplc)
albendazole sulfoxide, vetranal(tm), analytical standard
HMS3655E16
methyl [5-propylsulphinyl)-1h-benzimidazol-2-yl]carbamate
albendazole-sulfoxide
NCGC00386191-01
SW219539-1
DB13871
albendazole oxide (ricobendazole)
methyl (6-(propylsulfinyl)-1h-benzo[d]imidazol-2-yl)carbamate
Q27102154
albendazole-sulfoxide 100 microg/ml in acetonitrile
CCG-267255
ricobendazole; albendazole oxide
D81988
HY-12785
CS-0012454
albendazole-sulfoxide 1000 microg/ml in acetonitrile:methanol
122063-20-1
methyl n-[6-(propane-1-sulfinyl)-1h-1,3-benzodiazol-2-yl]carbamate
carbamic acid, n-[5-(propylsulfinyl)-1h-benzimidazol-2-yl]-, methyl ester?
SY059511
methyl 5-(propylsulfinyl)benzimidazole-2-carbamate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"A randomized, double-blind, placebo-controlled trial was conducted, to determine whether the co-administration of ivermectin with albendazole is safe and more effective against Onchocerca volvulus than ivermectin alone, and whether a significant pharmacokinetic interaction occurs."( The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.
Addy, ET; Ardrey, AE; Attah, SK; Awadzi, K; Duke, BO; Edwards, G; Opoku, NO; Quartey, BT, 2003
)
0.32

Pharmacokinetics

The pharmacokinetic behaviour of albendazole sulfoxide (ABZSO) enantiomers was studied in rats after the oral administration of 10 mg/kg of rac-ABZso. The interaction of ABZSO with dexamethasone, associated or not with cimetidine, was investigated.

ExcerptReferenceRelevance
" The half-life of albendazole sulphoxide was between 10 and 15 hours."( Clinical pharmacokinetics of albendazole in patients with brain cysticercosis.
Hurtado, M; Jung, H; Medina, MT; Sanchez, M; Sotelo, J, 1992
)
0.28
"Albendazole pharmacokinetic parameters were determined in lambs after iv, oral, and intraruminal single administrations."( Simultaneous pharmacokinetic modeling of a drug and two metabolites: application to albendazole in sheep.
Alvinerie, M; Francheteau, P; Galtier, P; Houin, G; Plusquellec, Y; Steimer, JL, 1991
)
0.28
"In a 4 x 4 crossover-design study, pharmacokinetic variables of 2 injectable formulations of netobimin (trisamine salt solution and zwitterion suspension) were compared after SC administration in calves at dosage of 12."( Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves.
Lanusse, CE; Prichard, RK; Ranjan, S, 1990
)
0.28
" Other pharmacokinetic parameters were comparable to those found in other studies."( Pharmacokinetics of albendazole in children with hydatid disease.
Hagos, B; Ng'ang'a, JN; Ogeto, JO; Okelo, GB, 1993
)
0.29
" The pharmacokinetic interaction of albendazole sulfoxide with dexamethasone, associated or not with cimetidine, was investigated in 24 patients with active intraparenchymal brain cysticercosis."( Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone.
Bonato, PS; Lanchote, VL; Marques, MP; Takayanagui, OM, 1997
)
0.81
" No statistically significant differences were found between the pharmacokinetic parameters of albendazole suphoxide (ABZSO) and albendazole sulphone (ABZSO2) among the three groups of ewes."( Comparative pharmacokinetics of netobimin metabolites in pregnant ewes.
Arboix, M; Carretero, A; Cristòfol, C; Franquelo, C; Navarro, M; Ruberte, J,
)
0.13
"05) was in the Tmax of the (-)-ABZSO."( Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep.
Arboix, M; Capece, BP; Castells, G; Cristòfol, C; Pérez, F, 2000
)
0.31
" The pharmacokinetic evaluation in each case was prepared by weighted least-squares nonlinear regression analysis."( Pharmacokinetics of ricobendazole in calves.
Errecalde, JO; Formentini, EA; Mariño, EL; Mestorino, ON, 2001
)
0.31
" The pharmacokinetic parameters were analyzed by analysis of variance followed by the Tukey-Kramer test."( Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis.
Dreossi, SA; Garcia, FS; Lanchote, VL; Takayanagui, OM, 2002
)
0.59
"A randomized, double-blind, placebo-controlled trial was conducted, to determine whether the co-administration of ivermectin with albendazole is safe and more effective against Onchocerca volvulus than ivermectin alone, and whether a significant pharmacokinetic interaction occurs."( The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.
Addy, ET; Ardrey, AE; Attah, SK; Awadzi, K; Duke, BO; Edwards, G; Opoku, NO; Quartey, BT, 2003
)
0.32
" Microsomal sulfonase activity can be abolished by in-vitro interaction with clotrimazole and pharmacokinetic studies confirm this interaction."( Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole.
Alvarez, AI; García, JL; Merino, G; Molina, AJ; Prieto, JG; Pulido, MM, 2003
)
0.32
" This work examines the mechanism involved in intestinal elimination of ABZSO and their pharmacokinetic consequences in rat and sheep."( Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors.
Alvarez, AI; García, JL; Merino, G; Molina, AJ; Prieto, JG; Pulido, MM, 2003
)
0.62
" No significant pharmacokinetic interaction between the albendazole and praziquantel was demonstrated."( Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis.
Chanthavanich, P; Kabkaew, K; Lapphra, K; Limkittikul, K; Na-Bangchang, K; Pengsaa, K; Pojjaroen-Anant, C; Sirivichayakul, C; Subchareon, A; Wisetsing, P, 2004
)
0.32
" The pharmacokinetic parameters were determined by compartmental analysis."( Pharmacokinetics of ricobendazole after its intravenous, intraruminal and subcutaneous administration in sheep.
Errecalde, JO; Formentini, EA; Mestorino, N, 2005
)
0.33
"The pharmacokinetic interactions and tolerability of albendazole, praziquantel and ivermectin combinations were assessed in 23 healthy Thai volunteers (12 males and 11 females)."( Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations.
Hanpitakpong, W; Kietinun, S; Lazdins, J; Na-Bangchang, C; Na-Bangchang, K; Pawa, KK, 2006
)
0.33
"The pharmacokinetic behaviour of albendazole sulfoxide (ABZSO) enantiomers was studied in rats after the oral administration of 10 mg/kg of rac-ABZSO, 5 mg/kg of (-)-ABZSO or 5 mg/kg of (+)-ABZSO."( Pharmacokinetics of albendazole sulfoxide enantiomers administered in racemic form and separately in rats.
Arboix, M; Capece, BP; Castells, G; Cristòfol, C; Godoy, C, 2008
)
0.95
" In all groups the area under the plasma concentration-time curve (AUC) and peak concentration (C(max)) values of (+)-ABZSO were significantly higher than those of (-)-ABZSO."( Effect of age and gender in the pharmacokinetics of albendazole and albendazole sulphoxide enantiomers in goats.
Afonso, SM; Capece, BP; Castells, G; Cristòfol, C; Godoy, C; Harun, M; Lazáro, R, 2009
)
0.35
"To determine a population pharmacokinetic model of the antihelmintic drug, albendazole, and identify the factors influencing the pharmacokinetic parameters in patients with neurocysticercosis."( Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Brundage, RC; Castro, N; Góngora, F; González-Esquivel, D; Jara, A; Jung, H; Lanao, JM; Márquez-Caraveo, C; Suárez, AM; Urizar, J, 2009
)
0.35
" Although none of the investigated covariates had a significant influence on the pharmacokinetic parameters of albendazole, the final model identified two subpopulations on the bioavailability parameter."( Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Brundage, RC; Castro, N; Góngora, F; González-Esquivel, D; Jara, A; Jung, H; Lanao, JM; Márquez-Caraveo, C; Suárez, AM; Urizar, J, 2009
)
0.35
" The developed assay was applied to a pharmacokinetic study in rats."( Highly sensitive LC-MS/MS-ESI method for simultaneous quantitation of albendazole and ricobendazole in rat plasma and its application to a rat pharmacokinetic study.
Giri, S; Kandaswamy, M; Meena, AK; Mithra, C; Mullangi, R; Rajagopal, S; Sharma, K, 2012
)
0.38
"In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW."( Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats.
Aksit, D; Ayaz, E; Boyacioğlu, M; Cirak, VY; Gokbulut, C; Sekkin, S; Yalinkilinc, HS, 2015
)
0.67
" Previous work has shown that the drug's pharmacologically active metabolite, albendazole sulfoxide, is characterised by substantial inter-individual pharmacokinetic variation."( Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis.
Basáñez, MG; Boussinesq, M; Chesnais, CB; Kamgno, J; Pion, SDS; Walker, M; Whittaker, C, 2022
)
0.95
" These data were then integrated into a mathematical modelling framework to infer albendazole sulfoxide pharmacokinetic parameters and relate them to characteristics of the groups being treated."( Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis.
Basáñez, MG; Boussinesq, M; Chesnais, CB; Kamgno, J; Pion, SDS; Walker, M; Whittaker, C, 2022
)
0.95

Compound-Compound Interactions

ExcerptReferenceRelevance
"In vitro assessment of drug candidates' affinity for multi-drug resistance proteins is of crucial importance for the prediction of in vivo pharmacokinetics and drug-drug interactions."( Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Gnoth, MJ; Grieshop, B; Ickenroth, K; Muenster, U, 2008
)
0.35
" In order to not overlook potential drug-drug interactions when testing drug candidates for inhibitory potential towards Bcrp, distinct Bcrp probe substrates should be used."( Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
Gnoth, MJ; Grieshop, B; Ickenroth, K; Muenster, U, 2008
)
0.35
" Overall, the results presented herein show that PCLS are a useful and reliable tool for short-term studies on metabolic drug-drug interactions in the bovine species."( Assessment of liver slices for research on metabolic drug-drug interactions in cattle.
García, JP; Lanusse, CE; Lifschitz, AL; Maté, ML; Quiroga, MA; Virkel, GL; Viviani, P, 2017
)
0.46
"The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
"In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
"In this research study, a method of dispersive-micro-solid phase extraction (D-µ-SPE) combined with molecularly imprinted polymer nanoparticles (MIP-NPs) with HPLC-UV was developed for the fast and selective detection of the trace amount of albendazole sulfoxide (ABZSO) in the biological samples."( A new approach for microextraction of trace albendazole sulfoxide drug from the samples of human plasma and urine, and water by the molecularly imprinted polymer nanoparticles combined with HPLC.
Alipanahpour Dil, E; Asfaram, A; Javadian, H, 2020
)
1
" This study aimed to explore the effects of ABZSO nanoparticles (ABZSO NPs), TPZ combined with PDT on the activity of Egs in vitro and in vivo."( Tirapazamine combined with photodynamic therapy improves the efficacy of ABZSO nanoparticles on Echinococcosis granulosus via further enhancing "breaking-then-curing".
Aimaiti, W; Gong, Y; Huang, Z; Jiang, H; Lin, Y; Wang, J; Wen, H; Xu, Y; Yang, J; Zhou, T, 2023
)
0.91
"ABZSO NPs combined with TPZ and PDT has a better inhibitory effect on the growth of Egs in vitro and in vivo based on the strategy of "breaking-then-curing"."( Tirapazamine combined with photodynamic therapy improves the efficacy of ABZSO nanoparticles on Echinococcosis granulosus via further enhancing "breaking-then-curing".
Aimaiti, W; Gong, Y; Huang, Z; Jiang, H; Lin, Y; Wang, J; Wen, H; Xu, Y; Yang, J; Zhou, T, 2023
)
0.91

Bioavailability

Albendazole sulfoxide (ABZSO) is the main intermediary metabolic product of ABZ. It is often used as a substitute for ABZ in metabolism and bioavailability research.

ExcerptReferenceRelevance
"The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of parenterally administered netobimin (NTB) and its major metabolites, albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO2), were studied in sheep."( Enhancement of the plasma concentration of albendazole sulphoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors.
Lanusse, CE; Prichard, RK, 1991
)
0.28
" The results also indicated that lower drug absorption rate and thickening of the adventitia during longer disease course are the two major factors affecting the efficacy of Meb and Alb, hence suggesting that increase of Meb absorption may be expected to raise the therapeutic effect of the drug."( Effects of benzimidazole compounds on mice infected with secondary cysts of Echinococcus granulosus.
Chai, JJ; Jiao, W; Shen, BG; Xiao, SH; Yang, YQ; You, JQ, 1994
)
0.29
" The corrected metabolite AUCs following NTB were, however, significantly lower than those following ABSO administration in 1-month-old lambs, suggesting that immature metabolic processes in these animals contributed to the lower relative bioavailability of NTB in this age group."( The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep.
Coop, RL; Jackson, F; McKellar, QA, 1995
)
0.51
" This work demonstrates the improvement of bioavailability when the ABZS is directly administered, compared with the ABZ administration, both orally given."( Bioavailability comparison between albendazole and albendazole sulphoxide in rats and man.
Dominguez, L; Fagiolino, P; Gordon, S; Manta, E, 1995
)
0.29
" The pharmacokinetic parameters maximum plasma concentration, time to maximum plasma concentration, absorption half-life, and absorption rate constant did not differ between groups, suggesting that the formation of albendazole sulfoxide was not altered by the administration of dexamethasone, combined or not with cimetidine."( Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone.
Bonato, PS; Lanchote, VL; Marques, MP; Takayanagui, OM, 1997
)
0.72
" Because benzimidazole anthelmintic drugs are generally administered orally, the ruminal flora play an important role in the bioavailability of these drugs."( Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen.
Arboix, M; Calsamiglia, S; Capece, BP; Castells, G; Cristòfol, C, 2001
)
0.54
" The data were subjected to pharmacokinetic analysis to compare the relative bioavailability and bioequivalence of AbzT and AbzE."( Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence.
Bin, L; Cheng, F; Hotez, P; Junjie, C; Mingjie, W; Shuhua, X; Weixia, S, 2002
)
0.31
"The effect of solubilization by complexation with povidone on the oral bioavailability of three anthelmintic benzimidazole carbamate drugs: mebendazole (MBZ), albendazole (ABZ) and ricobendazole (RBZ), was studied in mice."( The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs.
Cuesta-Bandera, C; Daniel-Mwambete, K; Ponce-Gordo, F; Torrado, JJ; Torrado, S, 2004
)
0.32
" These ABC drug efflux transporters extrude a wide range of xenotoxins from cells in intestine, liver, and other organs, thus affecting the bioavailability of many compounds."( Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Alvarez, AI; Jonker, JW; Merino, G; Molina, AJ; Pulido, MM; Schinkel, AH; Wagenaar, E, 2005
)
0.33
" Although none of the investigated covariates had a significant influence on the pharmacokinetic parameters of albendazole, the final model identified two subpopulations on the bioavailability parameter."( Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Brundage, RC; Castro, N; Góngora, F; González-Esquivel, D; Jara, A; Jung, H; Lanao, JM; Márquez-Caraveo, C; Suárez, AM; Urizar, J, 2009
)
0.35
"The aim of the study was to investigate the tissue tolerance and bioavailability of four formulations containing 5% ricobendazole solubilised at low pH, following subcutaneous injection in sheep."( Tissue compatibility and pharmacokinetics of three potential subcutaneous injectables for low-pH drug solutions.
McSporran, K; Medlicott, NJ; Razzak, M; Tucker, IG; Wu, Z, 2010
)
0.36
" Albendazole sulfoxide (ABZSO) is the main intermediary metabolic product of ABZ, and it is often used as a substitute for ABZ in metabolism and bioavailability research."( Comparative proteomics analysis of Trichinella spiralis muscle larvae exposed to albendazole sulfoxide stress.
Lv, P; Ming, L; Peng, RY; Ren, HJ; Wei, GH; Zhang, CL, 2018
)
1.62
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The aim of this study was to use a combined in vitro-in silico approach to develop a physiologically based pharmacokinetic model (PBPK) that predicts the bioavailability of albendazole (ABZ), a BCS class II/IV lipophilic weak base, and simulates its main metabolite albendazole sulphoxide (ABZSO) after oral administration of the current marketed dose of 400 mg in the fasted state."( A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide.
Bolger, MB; Chronowska, M; Kostewicz, ES; Pettarin, M, 2020
)
0.76

Dosage Studied

Age was significantly associated with variation in albendazole sulfoxide systemic availability and peak plasma concentration achieved. Age was also associated with the clearance rate (related to the half-life) after adjusting for variation in dosage due to differences in body weight between children and adults.

ExcerptRelevanceReference
"Five adult Saanen goats were dosed orally 3 times with albendazole (2."( Effect of repeated doses of albendazole on enantiomerism of its sulfoxide metabolite in goats.
Benoit, E; Besse, S; Delatour, P, 1992
)
0.28
"In a 4 x 4 crossover-design study, pharmacokinetic variables of 2 injectable formulations of netobimin (trisamine salt solution and zwitterion suspension) were compared after SC administration in calves at dosage of 12."( Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves.
Lanusse, CE; Prichard, RK; Ranjan, S, 1990
)
0.28
"Heifers were assigned at random to ABZ or control (water) groups, and were drenched with ABZ suspension at a dosage of 15, 30, 60, or 120 mg/kg of body weight, or with water."( Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers.
Bai, SA; Farin, CE; Piscopo, SE, 1997
)
0.58
"The influence of fasting prior to treatment and of dosing rate on the plasma availability and disposition kinetics of albendazole (ABZ) and its sulphoxide (ABZSO) and sulphone (ABZSO2) metabolites was studied in adult sheep grazing on pasture."( Enhanced plasma availability of the metabolites of albendazole in fasted adult sheep.
Lanusse, C; Lifschitz, A; Mastromarino, M; Virkel, G, 1997
)
0.3
" Non-pregnant ewes and ewes in the first and last third of pregnancy were dosed orally with 20 mg kg bodyweight of NTB."( Comparative pharmacokinetics of netobimin metabolites in pregnant ewes.
Arboix, M; Carretero, A; Cristòfol, C; Franquelo, C; Navarro, M; Ruberte, J,
)
0.13
" Plasma concentrations of albendazole-sulphoxide (ABZSO) were measured in age matched non-infected mice by high performance liquid chromatography (HPLC), after administration of ABZ or RBZ dosed at 50 mg ABZ equivalent kg-1."( Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice.
Bolás-Fernández, F; Lopez-Garcia, ML; Martínez-Fernández, AR; Torrado-Duran, J; Torrado-Duran, S, 1997
)
0.3
"Despite severe effects of ABZSO (> or = 1 microgram/ml) on bovine embryo development in vitro, it is beyond the scope of this study to speculate whether a therapeutic dosage of albendazole (10 mg/kg of body weight) would result in necessary concentrations of ABZSO in vivo to disrupt embryogenesis."( Comparison of effects of albendazole sulfoxide on in vitro produced bovine embryos and rat embryos.
Piscopo, SE; Smoak, IW, 1997
)
0.6
" Absorption was followed performing albendazole sulphoxide dosage in urine samples by high pressure liquid chromatography analysis, during 48 hours."( Lipidic matrix of albendazole sulphoxide: is it an alternative for systemic infections?
Camarote, C; Domínguez, L; Fagiolino, P; Malanga, A; Ochoa, A; Quevedo, D; Saldaña, J; Savio, E, 1998
)
0.3
"1 mg kg-1) to Merino sheep, the AUC0-infinity of albendazole sulphoxide at the lower dosage of netobimin, was significantly increased (75."( Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration.
Alvarez, AI; Garcia, JL; Larrodé, OM; Merino, G; Prieto, JG; Redondo, PA, 1999
)
0.3
" Within each period two fermenters per treatment were immediately dosed with 104 mg of netobimin, 52 mg of albendazole, or 39 mg of albendazole sulfoxide."( Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen.
Arboix, M; Calsamiglia, S; Capece, BP; Castells, G; Cristòfol, C, 2001
)
0.74
" The combination does not require an alteration in the dosage of either component."( The co-administration of ivermectin and albendazole--safety, pharmacokinetics and efficacy against Onchocerca volvulus.
Addy, ET; Ardrey, AE; Attah, SK; Awadzi, K; Duke, BO; Edwards, G; Opoku, NO; Quartey, BT, 2003
)
0.32
" The procedure was applied to the determination of albendazole and its 3 metabolites in the muscle tissue of the 2 fish species after orally dosing them with albendazole."( Determination of albendazole and its metabolites in the muscle tissue of hybrid striped and largemouth bass using liquid chromatography with fluorescence detection.
Rummel, N; Shaikh, B,
)
0.13
"05) higher AUC, C(max) and mean residence time values were observed after the administration of the highest dosage level."( Dose-dependent systemic exposure of albendazole metabolites in lambs.
Alvarez, L; Ceballos, L; Lanusse, C; Moreno, L; Suárez, G, 2012
)
0.38
" In a last study with this formulation, this active principle was administered orally, mixed with the mineral supplement, on the 60th DPI, in a dosage of 30mg/kg."( Historic of therapeutic efficacy of albendazol sulphoxide administered in different routes, dosages and treatment schemes, against Taenia saginata cysticercus in cattle experimentally infected.
Buzzulini, C; Cruz, BC; da Costa, AJ; de Oliveira, GP; Felippelli, G; Lopes, WD; Maciel, WG; Nunes, JL; Pereira, JC; Soares, VE; Soccol, VT; Teixeira, WF, 2014
)
0.4
" Among the same dosage groups, the inhibition rate in ABZ-CS-MPs group (from low to high dosage sub-group: 91."( [Efficacy of albendazole chitosan microspheres against Echinococcus granulosus infection in mice].
Liang, W; Ma, X; Peng, XY; Sun, H; Wang, XC; Wu, XW; Zhang, SJ, 2014
)
0.4
"This paper describes a melting solidification printing process (MESO-PP) capable of obtaining printed oral solid dosage forms in a safe, versatile, and robust manner avoiding the use of solvents and high temperatures."( Design of novel oral ricobendazole formulation applying melting solidification printing process (MESO-PP): An innovative solvent-free alternative method for 3D printing using a simplified concept and low temperature.
Barberis, ME; Camacho, NM; Palma, SD; Real, JP; Sánchez Bruni, S, 2020
)
0.56
" Age was significantly associated with variation in albendazole sulfoxide systemic availability and peak plasma concentration achieved; as well as the clearance rate (related to the half-life) after adjusting for variation in dosage due to differences in body weight between children and adults."( Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis.
Basáñez, MG; Boussinesq, M; Chesnais, CB; Kamgno, J; Pion, SDS; Walker, M; Whittaker, C, 2022
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.06680.006038.004119,952.5996AID1159521
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.53580.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency22.20800.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.60320.003041.611522,387.1992AID1159552; AID1159555
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency33.49150.005428.02631,258.9301AID1346982
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
histone deacetylase 9 isoform 3Homo sapiens (human)Potency5.73570.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency13.33220.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID372905Octanol-water partition coefficient, log P of the compound2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and in vitro cysticidal activity of new benzimidazole derivatives.
AID680977TP_TRANSPORTER: transepithelial transport (basal to apical) in BCRP-expressing MDCKII cells2005Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID372901Antiparasitic activity against Taenia crassiceps cysts ORF strain assessed as cysts mortality at 0.28 uM after 11 days by Trypan blue exclusion test2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and in vitro cysticidal activity of new benzimidazole derivatives.
AID372902Antiparasitic activity against Taenia crassiceps cysts ORF strain assessed as cysts mortality at 1.70 uM after 11 days by Trypan blue exclusion test2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and in vitro cysticidal activity of new benzimidazole derivatives.
AID372903Antiparasitic activity against Taenia crassiceps cysts WFU strain assessed as cysts mortality at 0.28 uM after 11 days by Trypan blue exclusion test2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and in vitro cysticidal activity of new benzimidazole derivatives.
AID372904Antiparasitic activity against Taenia crassiceps cysts WFU strain assessed as cysts mortality at 1.70 uM after 11 days by Trypan blue exclusion test2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and in vitro cysticidal activity of new benzimidazole derivatives.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID679782TP_TRANSPORTER: transepithelial transport (basal to apical) in Bcrp1-expressing MDCKII cells2005Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (250)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (8.80)18.7374
1990's62 (24.80)18.2507
2000's80 (32.00)29.6817
2010's66 (26.40)24.3611
2020's20 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.99 (24.57)
Research Supply Index5.64 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (8.49%)5.53%
Reviews3 (1.16%)6.00%
Case Studies2 (0.77%)4.05%
Observational0 (0.00%)0.25%
Other232 (89.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]